Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 17 April 2018, 20:45 HKT/SGT

Source: Jacobson Pharma Corporation
Jacobson Pharma Ranked No.1 in "Hong Kong Best Small-Cap Company" in the "Asia's Best Companies Poll 2018" by FinanceAsia

HONG KONG, Apr 17, 2018 - (Media OutReach) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, is pleased to announce that Jacobson Pharma ranked no.1 in the category of Hong Kong Best Small-Cap Company in the "Asia's Best Companies Poll 2018" conducted by FinanceAsia, an authoritative financial magazine in Asia.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, "We are very proud of being ranked no.1 of the Best Small-cap Company and gain strong recognition in the investment community. This is also a clear acknowledgment of our dedication to excellence in all aspects of corporate management and corporate governance. I would like to take this opportunity to thank all investors and analysts who have cast their vote for Jacobson Pharma for their ongoing support and solid confidence in the Group's bright prospects.

Looking ahead, the management team will continue to strive for a healthy business momentum and realize the growth strategies in line with our original plans and schedule. We will continue to take a measured and disciplined approach to R&D investment as well as expand our footprint in certain strategic markets in Asia with a view to creating sustainable value for our shareholders".

Jacobson Pharma reported sound financial results for the six months ended 30 September 2017, with the Group's revenue increasing by 29.1% to HK$743.0 million. Profit attributable to the shareholders of the Group surged by 40.6% to HK$80.3 million.

Asia's Best Companies Poll 2018, held for the eighteenth consecutive year, is conducted by the leading regional financial publication FinanceAsia. All of the awards were nominated and voted by institutional investors or analysts from across Asia. Investment professionals are requested to rank companies in key categories, including corporate governance, investor relations, commitment to dividends, etc.

For more details about the Asia's Best Companies Poll 2018 results, please visit:

About Jacobson Pharma Corporation Limited (Stock Code: 2633)

Jacobson Pharma is the largest generic drug company in Hong Kong with over 30% share of the total generic drug market for each year since 2012. The Group's proprietary medicines, notably being Po Chai Pills, Tong Tai Chung Woodlok Oil, Ho Chai Kung Tji Thung San, Contractubex Scar Gel, Doan's Ointment, Flying Eagle Wood Lok Medicated Oil, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognised by the market. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website:

For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email:
Angela Ng Tel: (852) 2864 4855 Email:
Queenie Chan Tel: (852) 2864 4851 Email:
Fax: (852) 2527 1196

Apr 17, 2018 20:45 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, HealthCare
From the Asia Corporate News Network

Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Jacobson Pharma Corporation
Nov 21, 2018 22:43 HKT/SGT
Jacobson Pharma Announces FY2019 Interim Results
June 25, 2018 22:00 HKT/SGT
Jacobson Pharma Announces 2018 Annual Results
June 25, 2018 20:48 HKT/SGT
Jacobson Pharma Announces 2018 Annual Results
June 14, 2018 06:00 HKT/SGT
Jacobson Pharma Updates on TAILORx Study
June 13, 2018 23:50 HKT/SGT
Jacobson Pharma Updates on TAILORx Study
Apr 17, 2018 18:30 HKT/SGT
Jacobson Pharma Ranked No. 1 in "Hong Kong Best Small-Cap Company" in the "Asia's Best Companies Poll 2018" by FinanceAsia
Dec 20, 2017 23:00 HKT/SGT
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market
Dec 20, 2017 21:58 HKT/SGT
Jacobson Pharma Enters Agreements with Shanghai Henlius Biotech Inc. To Tap Biologics Market
Nov 22, 2017 22:12 HKT/SGT
Jacobson Pharma Announces FY2018 Interim Results
Oct 3, 2017 17:44 HKT/SGT
Jacobson Pharma Issues HK$500M Convertible Notes to Dragons 615 Ltd and HH InRe JP, Ltd.
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: